Daisy Carvajal

7.8k total citations · 2 hit papers
18 papers, 6.5k citations indexed

About

Daisy Carvajal is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Daisy Carvajal has authored 18 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Daisy Carvajal's work include Immune Cell Function and Interaction (8 papers), T-cell and B-cell Immunology (7 papers) and Cancer-related Molecular Pathways (5 papers). Daisy Carvajal is often cited by papers focused on Immune Cell Function and Interaction (8 papers), T-cell and B-cell Immunology (7 papers) and Cancer-related Molecular Pathways (5 papers). Daisy Carvajal collaborates with scholars based in United States, Switzerland and Germany. Daisy Carvajal's co-authors include Binh Thanh Vu, Frank Podlaski, Lyubomir T. Vassilev, Christine Lukacs, Emily A. Liu, Nader Fotouhi, Norman Kong, Zoran Filipovic, Bradford Graves and Christian Klein and has published in prestigious journals such as Science, Journal of Biological Chemistry and Immunity.

In The Last Decade

Daisy Carvajal

18 papers receiving 6.4k citations

Hit Papers

In Vivo Activation of the... 1996 2026 2006 2016 2004 1996 1000 2.0k 3.0k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daisy Carvajal United States 17 3.7k 3.1k 1.8k 631 501 18 6.5k
Frank Podlaski United States 22 3.8k 1.0× 3.2k 1.0× 2.1k 1.2× 653 1.0× 505 1.0× 26 7.2k
Shiro Akinaga Japan 43 3.7k 1.0× 1.8k 0.6× 1.7k 1.0× 381 0.6× 194 0.4× 122 6.6k
Victor S. Goldmacher United States 44 2.8k 0.7× 2.5k 0.8× 1.6k 0.9× 278 0.4× 600 1.2× 90 6.6k
Allen Oliff United States 43 4.1k 1.1× 2.6k 0.8× 883 0.5× 562 0.9× 210 0.4× 107 6.7k
Robin Fåhræus France 44 3.1k 0.9× 2.9k 0.9× 1.0k 0.6× 632 1.0× 257 0.5× 136 5.7k
Hartmut Koeppen United States 30 3.5k 1.0× 3.0k 1.0× 1.9k 1.0× 992 1.6× 346 0.7× 62 6.4k
Sonia Laı́n United Kingdom 40 4.2k 1.1× 2.8k 0.9× 433 0.2× 667 1.1× 764 1.5× 83 6.8k
K E Hellström United States 47 3.0k 0.8× 2.0k 0.7× 3.1k 1.7× 244 0.4× 446 0.9× 106 7.1k
Catherine L. Day New Zealand 38 6.1k 1.6× 1.8k 0.6× 1.2k 0.7× 745 1.2× 146 0.3× 81 7.4k
Yuval Reiss Israel 24 4.7k 1.3× 2.2k 0.7× 793 0.4× 573 0.9× 206 0.4× 37 6.1k

Countries citing papers authored by Daisy Carvajal

Since Specialization
Citations

This map shows the geographic impact of Daisy Carvajal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daisy Carvajal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daisy Carvajal more than expected).

Fields of papers citing papers by Daisy Carvajal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daisy Carvajal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daisy Carvajal. The network helps show where Daisy Carvajal may publish in the future.

Co-authorship network of co-authors of Daisy Carvajal

This figure shows the co-authorship network connecting the top 25 collaborators of Daisy Carvajal. A scholar is included among the top collaborators of Daisy Carvajal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daisy Carvajal. Daisy Carvajal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Vicente, Javier de, David Bolin, Daisy Carvajal, et al.. (2015). Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors. ACS Medicinal Chemistry Letters. 6(9). 1019–1024. 18 indexed citations
2.
He, Wei, Malcolm J. Bennett, Leopoldo Luistro, et al.. (2013). Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability. Molecular Therapy. 22(2). 359–370. 58 indexed citations
3.
He, Wei, Leopoldo Luistro, Daisy Carvajal, et al.. (2011). High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097. Molecular Oncology. 5(3). 292–301. 38 indexed citations
4.
Kolinsky, Kenneth, Christian Tovar, Yue Zhang, et al.. (2011). Preclinical evaluation of the novel multi-targeted agent R1530. Cancer Chemotherapy and Pharmacology. 68(6). 1585–1594. 10 indexed citations
5.
Luistro, Leopoldo, Wei He, Melissa Smith, et al.. (2009). Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties. Cancer Research. 69(19). 7672–7680. 154 indexed citations
6.
Ambrosini, Grazia, Elliot B. Sambol, Daisy Carvajal, et al.. (2006). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 26(24). 3473–3481. 129 indexed citations
7.
Carvajal, Daisy, Christian Tovar, Hong Yang, et al.. (2005). Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors. Cancer Research. 65(5). 1918–1924. 159 indexed citations
8.
Vassilev, Lyubomir T., Binh Thanh Vu, Bradford Graves, et al.. (2004). In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 303(5659). 844–848. 3722 indexed citations breakdown →
9.
Thompson, Thelma, Christian Tovar, Hong Yang, et al.. (2004). Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis. Journal of Biological Chemistry. 279(51). 53015–53022. 198 indexed citations
10.
11.
Gately, Maurice K., Daisy Carvajal, Suzanne E. Connaughton, et al.. (1996). Interleukin‐12 Antagonist Activity of Mouse Interleukin‐12 p40 Homodimer in Vitro and in Vivo. Annals of the New York Academy of Sciences. 795(1). 1–12. 118 indexed citations
12.
Wu, Chang‐You, Rajeev R. Warrier, Daisy Carvajal, et al.. (1996). Biological function and distribution of human interleukin‐12 receptor β chain. European Journal of Immunology. 26(2). 345–350. 74 indexed citations
13.
Magram, Jeanne, Suzanne E. Connaughton, Rajeev R. Warrier, et al.. (1996). IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses. Immunity. 4(5). 471–481. 890 indexed citations breakdown →
14.
Magram, Jeanne, Suzanne E. Connaughton, D A Faherty, et al.. (1996). IL‐12‐Deficient Mice Are Defective but Not Devoid of Type 1 Cytokine Responses. Annals of the New York Academy of Sciences. 795(1). 60–70. 97 indexed citations
15.
Gillessen, Silke, Daisy Carvajal, Ping Ling, et al.. (1995). Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist. European Journal of Immunology. 25(1). 200–206. 391 indexed citations
16.
Tare, Nadine S., Rajeev R. Warrier, Daisy Carvajal, et al.. (1995). Administration of Recombinant Interleukin-12 to Mice Suppresses Hematopoiesis in the Bone Marrow but Enhances Hematopoiesis in the Spleen. Journal of Interferon & Cytokine Research. 15(4). 377–383. 48 indexed citations
17.
Zou, Jun, David S. Schoenhaut, Daisy Carvajal, et al.. (1995). Structure-Function Analysis of the p35 Subunit of Mouse Interleukin 12. Journal of Biological Chemistry. 270(11). 5864–5871. 33 indexed citations
18.
Gately, Maurice K., Rajeev R. Warrier, Daisy Carvajal, et al.. (1994). Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. International Immunology. 6(1). 157–167. 332 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026